GALE Human Gene Knockout Kit (CRISPR)

CAT#: KN201561RB

GALE - human gene knockout kit via CRISPR, HDR mediated

Functional Cassette: GFP-puro Luciferase-Puro RFP-BSD mBFP-Neo



HDR-mediated knockout kit validation

  See Other Versions

USD 1,657.00

2 Weeks*

Size
    • 1 kit

Product Images

Frequently bought together (3)
pCAS-Scramble, pCas-Guide vector with a scrambled sequence as a negative control (10 µg)
    • 10 ug

USD 450.00


GALE mouse monoclonal antibody, clone OTI1C4 (formerly 1C4)
    • 100 ul

USD 447.00


GALE (Myc-DDK-tagged)-Human UDP-galactose-4-epimerase (GALE), transcript variant 1
    • 10 ug

USD 457.00

Other products for "GALE"

Specifications

Product Data
Format 2 gRNA vectors, 1 RFP-BSD donor, 1 scramble control
Donor DNA RFP-BSD
Symbol GALE
Locus ID 2582
Components

KN201561G1, GALE gRNA vector 1 in pCas-Guide CRISPR vector

KN201561G2, GALE gRNA vector 2 in pCas-Guide CRISPR vector

KN201561RBD, donor DNA containing left and right homologous arms and RFP-BSD functional cassette.

GE100003, scramble sequence in pCas-Guide vector

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
Reference Data
RefSeq NM_000403, NM_001008216, NM_001127621
UniProt ID Q14376
Synonyms SDR1E1
Summary This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and cognitive disability, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified. [provided by RefSeq, Jul 2008]

Other Versions

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.